Five newcos developing iPS cell-derived therapies for cancer

At least five companies launched since 2019 are using induced pluripotent stem (iPS) cells to create immune cell therapies for cancer.

iPS cells can differentiate into any cell type in the body and proliferate indefinitely in culture, offering a potentially limitless source of starting material for the production of homogenous populations of therapeutic cells...